UC San Diego School of Medicine researchers report that stool microbiomes of NAFLD patients are distinct enough to potentially be used to accurately predict which persons with NAFLD are at greatest risk for having cirrhosis.
A first-in-class clinical trial suggests a novel treatment measurably slowed progression of non-alcoholic fatty liver disease to its more progressive and deadly form.
Researchers at UC San Diego School of Medicine, with colleagues elsewhere, will receive almost $19 million over five years for the fourth phase of the Vietnam Era Twin Study of Aging, which investigates cognition, aging and the risk for mild cognitive impairment and Alzheimer’s disease.
Using induced pluripotent stem cells (iPSCs) and deleting a key gene, researchers at University of California San Diego School of Medicine have created natural killer cells — a type of immune cell — with measurably stronger activity against a form of leukemia, both in vivo and in vitro.
Dr. Cheryl Anderson, professor and interim chair of the Department of Family Medicine and Public Health in the School of Medicine at the University of California San Diego, has been named founding dean of The Herbert Wertheim School of Public Health and Human Longevity Science.
UC San Diego researchers have identified small molecules in the blood of asymptomatic pregnant women that may predict risk for preeclampsia, responsible for a significant proportion of maternal and neonatal deaths, low birth weight and is a primary cause of premature birth.
The NIH has launched a major clinical trial to assess the malaria drug hydroxychloroquine and antibiotic azithromycin as a treatment for COVID-19. The trial will recruit 2,000 participants at 30 sites. A Q&A with the trial’s team leader: Davey Smith, MD, of UC San Diego School of Medicine.
Program makes COVID-19 testing available to thousands of students in effort to track the novel coronavirus and better position the campus to resume in-person activities in the fall.
The Altman Clinical and Translational Research Institute at University of California San Diego has received a five-year, $54.7 million Clinical and Translational Science Award from the National Center for Advancing Translational Science (NCATS), part of the National Institutes of Health.
UC San Diego scientists have launched a clinical trial to investigate whether a drug approved for treating high blood pressure might also reduce the severity of COVID-19 infections, lowering rates for intensive care unit admissions, the use of mechanical ventilators and all-cause mortality.